2019年方案

Cambridge Healthtech Institute’s 14th Annual

Neurotech Investing and Partnering Conference

透过投资与合作推动神经科技的进步

2019年5月21-22日


Neurotech Investing and Partnering Conference为国际论坛,开发对应脑与神经系统疾病的新疗法与诊断方式的投资者、创业者、企业干部、研究人员等将齐聚一堂,思考隶属组织与产业的未来。

本会议是讨论神经科技市场划定的场所,阐明相关业界现状的主题演讲、持有最先端技术的企业展演、主要转译研究计画的介绍、重要主题的专题讨论都在预定之中。

Final Agenda

7:30 am Conference Registration and Continental Breakfast

8:30 State of the Neurotech Industry

Guest speakers provide an annual review of trends and developments in neurotech.

Speaker: Harry Tracy, President, NI Research

9:00 Investing in Neurotech Panel

A diverse panel of private, public and strategic investors will discuss their investment strategies. What does it take to get a neurotech company funded? What are the benefits and risks of business models in devices, pharmaceuticals, diagnostics and information technology? What are today’s deal terms and valuations? What are the best exit strategies and how is neurotech comparing to other industries?

Moderator: Bruce Leutcher, MD, Partner, PJT Partners

Panelists: Jamil Beg, Principal, 5AM Ventures

Laura Tadvalkar, PhD, Senior Associate, MP Health Partners

Deanna Belsky, PhD, Associate, Dolby Family Ventures

Maria Shepherd, Principal, Mass Medical Angels

10:00 Coffee Break with Exhibit Viewing

10:45 Treatments for Alzheimer’s and Cognitive Disorders

As the population ages, the market for neurodegenerative disorders is exploding. Current treatments stabilize symptoms only for a short period of time. What is on the horizon for symptom improvement and disease modification from drug and device companies? Can earlier or more accurate diagnosis improve outcomes?

Moderator: Ian N. Kremer, Executive Director, LEAD Coalition (Leaders Engaged on Alzheimer’s Disease)

Speakers: Zach Malchano, CEO, Cognito

Martin Tolar, MD, PhD, CEO, Alzheon

James G. Moe, PhD, MBA, President & CEO, Oligomerix

Michael Szulczewski, President, Gliacure

11:45 Developments on the Horizon for Pain and Epilepsy

Drugs and devices with novel mechanisms of action are on the horizon to decrease side effects and improve efficacy in treatment-resistant populations for epilepsy and neuropathic pain. Hear from leading companies on their approaches.

Moderator: Kerrie Brady, MBA, Chief Business Officer, Executive Vice President, Corporate Strategy, Centrexion

Speaker: Angelique Johnson, PhD, CEO, MEMstim

12:45 pm Networking Luncheon

2:00 Internal and External Research and Development

Pharmaceutical and device companies are looking to provide complete solutions that span from prevention to treatment. Functions across the value chain will be kept in-house or partnered. This panel of experts will discuss how they approach collaborations with other companies, academic groups, research institutes and platform companies.

Moderator: Michael Kandra, Director, Business Development, Allen Brain Institute

Panelists: Eric Schaeffer, PhD, Senior Director of Neuroscience Innovation, Johnson & Johnson Innovation

Pierandrea Muglia, MD, Vice President & Head Neuroscience Discovery Medicine, UCB Pharma

Jeff Erb, Senior Director, Strategy and Business Development, Medtronic

3:00 Refreshment Break with Exhibit Viewing

3:30 Targeting Orphan Diseases

Orphan disorders are a hot area of investment due to perceived benefits with regulatory agencies, ready access to patients, and premium pricing. This session will gather companies developing treatments for ALS, lysosomal storage disorders, Huntington’s, and more.

Moderator: Nicole Johnson, Founder, FOXG1 Research Foundation

Speakers: Lynn Durham, CEO & Founder, Stalicla

Sylvain Lengacher, PhD, CEO & Co-Founder, GliaPharm

Anthony R. DePasqua, MBA, Co-Founder and CEO, EnClear

4:30 Strategic Development of Your Product Outside of the US: The Australian Advantage

Tina Soulis, PhD, CEO, Neuroscience Trials Australia

4:45 Emerging Company Showcase

The fourth annual Emerging Company Showcase offers the stage to young neurotech companies to pitch their drug, device, diagnostic, or software to an audience of investors, CEOs, and executives in the field. Please view the event website for a full list of this year’s presenters.

5:30 Welcome Reception with Exhibit Viewing

6:30 Close of Day

8:00 am Continental Breakfast

8:30 KEYNOTE PRESENTATION: Translating Neurotechnology from the Lab to the Clinic

John Donoghue, PhD, Director, Wyss Center for Bio and Neuroengineering

9:00 Partnering and Licensing in Neurotech Panel

Big pharma, biotech and medtech need to act to capitalize new innovations that provide solutions to the global demands in healthcare. This insider panel will discuss their areas of interest for in-licensing novel therapeutics, devices and diagnostics, and what they look for in a partner.

Moderator: Christine de los Reyes, Vice President, Strategic Planning & Business Development, Alopexx Enterprises

Panelists: Atsushi Hashimoto, Director, Business Development, Mitsubishi Tanabe Pharma

Robert Bagdorf, MD, MBA, Vice President, Global Business Development, Pfizer

Nicholas Scarchilli, Director, Business Development, Biogen

10:00 Coffee Break with Exhibit Viewing

10:45 Next Generation Psychiatry

Schizophrenia, anxiety, depression, addiction, ADHD and other psychiatric illnesses represent a large portion of the neurotech market. Development of promising next-generation treatments is challenging. Novel devices and diagnostics are poised to change the treatment landscape. This session will gather the most innovative treatments for mental health disorders.

Moderator: Manuel Lopez Figueroa, PhD, Managing Director, Bay City Capital

Speakers: David Baker, COO and Acting CEO, Vallon Pharma

Ekaterina Malievskaia, MD, MSc, CMO and Co-Founder, Compass Pathways

Teresa Tarrago, PhD, CEO and Co-Founder, iProteos

Emer Leahy, PhD, MBA, President and CEO, Psychogenics

11:45 Frontiers in Neurotechnology

In this session we will hear from companies on the cutting edge. Artificial Intelligence (AI) applications, novel neurostimulation devices developed for new markets, closed loop systems create the promise of reduced side effects and more targeted treatment. New technology is yielding benefits in discovery and delivery of therapeutics to brain. This session will preview of next generation products and companies in neurotechnology.

Moderator to be Announced

Speakers: Alice Zhang, CEO, Verge Therapeutics

Bob Cathcart, President and CEO, AIM Medical Robotics

12:45 pm Networking Luncheon

2:00 Parkinson’s and Other Movement Disorders

Current treatments for movement disorders can improve functioning but suffer from side effects and “off” periods, especially as the disease progresses. A number of novel pipeline pharmaceuticals and devices seek to address these issues. This session will explore how disease-modifying treatments alter the course of movement disorders and how companion diagnostics can be leveraged to provide the most optimal outcome for patients.

Moderator: Wasim Q. Malik, PhD, Managing Partner, Iaso Ventures

Speaker: Adrien Chatillon, CEO, ActiPulse

3:00 NINDS Panel

The small business program at NINDS is used to achieve the mission of the Institute by supporting innovative ideas at different stages of development, including applied bench research, translational research, and early stage clinical trials.

Moderator: Stephanie Fertig, Director, NINDS Small Business Programs

4:00 Close of Conference

* 活动内容有可能不事先告知作更动及调整。

Choose your language
Chinese
Japanese
Korean
English





免费电子邮件通知服务